USRE43691E1 - C1 inhibitor with short half-life transient treatment - Google Patents

C1 inhibitor with short half-life transient treatment Download PDF

Info

Publication number
USRE43691E1
USRE43691E1 US13/157,176 US200413157176A USRE43691E US RE43691 E1 USRE43691 E1 US RE43691E1 US 200413157176 A US200413157176 A US 200413157176A US RE43691 E USRE43691 E US RE43691E
Authority
US
United States
Prior art keywords
inhibitor
life
derived
plasma
individual
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US13/157,176
Other languages
English (en)
Inventor
Johannes Henricus Nuijens
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharming Intellectual Property BV
Original Assignee
Pharming Intellectual Property BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharming Intellectual Property BV filed Critical Pharming Intellectual Property BV
Priority to US13/157,176 priority Critical patent/USRE43691E1/en
Application granted granted Critical
Publication of USRE43691E1 publication Critical patent/USRE43691E1/en
Assigned to SILICON VALLEY BANK reassignment SILICON VALLEY BANK SECURITY INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: PHARMING INTELLECTUAL PROPERTY B.V.
Assigned to ORBIMED ROYALTY OPPORTUNITIES II, LP reassignment ORBIMED ROYALTY OPPORTUNITIES II, LP AMENDED AND RESTATED INTELLECTUAL PROPERTY SECURITY AGREEMENT Assignors: PHARMING INTELLECTUAL PROPERTY B.V.
Assigned to PHARMING INTELLECTUAL PROPERTY B.V., PHARMING TECHNOLOGIES B.V., PHARMING GROUP N.V., PHARMING B.V., PHARMING HEALTHCARE, INC., BROEKMAN INSTITUUT B.V., PHARMING AMERICAS B.V. reassignment PHARMING INTELLECTUAL PROPERTY B.V. RELEASE BY SECURED PARTY (SEE DOCUMENT FOR DETAILS). Assignors: ORBIMED ROYALTY OPPORTUNITIES II, LP
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Definitions

  • the present invention relates to the controlled delivery of a pharmaceutical composition.
  • it relates to the controlled delivery of a pharmaceutical composition which comprises a glycoprotein.
  • a particularly high dose of a pharmaceutically active compound may be administered to ensure that at least an effective amount of it reaches the desired site of treatment.
  • This approach to administration is clearly problematic, because at high dose the pharmaceutically active compound may exerts its detrimental effects.
  • Circulation 104:3125 They describe how C1INH significantly protects ischemic tissue from reperfusion damage at 40 IU/kg, but provokes detrimental effects at overly high doses (a dose of 100 IU/kg or more).
  • FIG. 1 shows the time profiles of mean functional C1INH (U/mL) in the distinct dosage groups.
  • the SD in the highest dosage group (100 U/kg) is presented by a bar.
  • FIG. 2 shows the time profiles of mean normalised C4 antigen (%) in the distinct dosage groups.
  • the SD in the highest dosage group (100 U/kg) is presented by a bar.
  • FIG. 3 shows the time profiles of mean C4b/c (nmol/mL) in the distinct dosage groups during the first 8 hours post-infusion.
  • the SD in the lowest dosage group (6.25 U/kg) is presented by a bar.
  • the present invention relates to the use of a C1 inhibitor (C1INH) with shorter half-life than its naturally occurring counterpart for the preparation of a medicament for the transient treatment of an individual.
  • C1INH C1 inhibitor
  • naturally occurring counterpart refers to naturally occurring C1INH which is typically derived from plasma.
  • treatment refers to treatment of individuals who are already with the disorder as well as those susceptible to the disorder or those in which the disorder is to be prevented. In other words, it relates to both therapeutic and prophylactic treatment.
  • transient treatment refers to the administration of C1INH at certain therapeutic levels for a concise pre-determined time-span.
  • individual refers to any individual, both human and non-human, both young and old, both ill and asymptomatic.
  • half-life refers to the amount of time after which half of the total amount of C1INH brought in circulation has been cleared from the blood stream.
  • the protein sequence of a C1INH with shorter half-life is typically the same or substantially the same, i.e. more than 70%, preferably more than 80, 85, 90 or 95% the same as the protein sequence of plasma-derived C1INH. It may have been obtained from plasma derived C1INH after modification, but also by independent production.
  • the advantage of the use according to the invention is that an individual is not exposed to C1INH for longer than required, since the levels of C1INH more rapidly subside after administration has stopped. In contrast, levels of plasma-derived C1INH would remain elevated for a prolonged period of time. This may be unnecessary or be associated to certain health risks.
  • the use of C1INH with a shorter half-life may result in a better ratio of beneficial effects and adverse reactions. This high initial dose may be at least 1,5, at least 2, 3 or 4 times the dosis of the natural occurring counterpart which would be administered.
  • the use of proteins with a shorter half-life allows for the exposure of an individual to an active compound at a certain level for a concise predetermined time span.
  • Transient treatment may be essential or highly desired if the individual who receives the treatment is already weak or infirm. Such may be the case if the individual is of high age or very young, e.g. a new born or is weakened, e.g. due to a condition or disease, or even due to other treatments.
  • Transient treatment may also be essential if the pharmaceutical agent which is used for treatment is very strong and demanding on the receiving individual. Unnecessary long exposure of an individual to such pharmaceutical agents should be prevented as much as possible.
  • the C1INH with shorter half-life may, for instance, be coupled to a cytostatic agent or to an isotope which should be removed from circulation as soon as possible after its has had its effect, to avoid detrimental side-effects caused by this cytotoxic compound as much as possible.
  • Transient treatment also allows for the treatment of a condition or disease which requires precise control of the dosage of the medicament, such as when working with pharmaceutical agents which posses a very narrow range of therapeutic effectiveness.
  • some drugs require a large amount to be injected in the blood stream to ensure that an adequate dose and concentration will be delivered to the affected area.
  • the drugs may cause side effects on other organs in the body, particularly if they remain present after the therapeutic effect has been achieved.
  • the use of the present invention reduces the risks of side effects, since the drug with the shorter half-life is more rapidly cleared from the body than its counterpart with the longer half-life. This means that the drug is cleared after it has exerted its beneficial effects and its presence is not considered necessary anymore.
  • Transient treatment may also be used in acute cases where a high initial dose is required or advantageous for successful treatments.
  • a C1INH with shorter half-life may be prepared by any convenient method. It may for example be prepared by in vivo or in vitro modification of its carbohydrate structure. Modifications to the carbohydrate structure include modifications which lead to underglycosylation, overglycosylation, to the asialio form of C1INH, or any other modifications which lead to a different glycosylation pattern.
  • underglycosylation may be the result of a deletion of a carbohydrate moiety or of a complete carbohydrate chain of C1INH. Modifications may involve both N- or O-linked carbohydrate chains, or only one type of chain. It may involve all the chains, or only some of the chains. Overglycosylation may for instance be the result of the addition of an extra carbohydrate moiety or a complete carbohydrate chain to the C1INH molecule.
  • An asialo-form of C1INH may typically be obtained by removal of a sialic acid group. It is well-known that the half-life of a glycoprotein in the blood is highly dependent on the composition and structure of its N- and O-linked carbohydrate groups.
  • Sialic acid may be removed in several ways. For instance, it may be removed chemically or enzymatically, for example, by treatment with sialidase.
  • modifications of carbohydrate chains of C1INH may be introduced by using recombinant production systems.
  • prokaryotic and eukaryotic cell cultures may be used, such as yeast cells, fungal cells, insect cells and mammalian cells.
  • yeast cells such as yeast cells, fungal cells, insect cells and mammalian cells.
  • COS cells and CHO cells are suitable mammalian production systems.
  • mammalian cell culture systems have the capacity to produce glycoproteins with sialylated carbohydrate groups, optimal, natural or complete glycosylation is often difficult to achieve and consequently, recombinantly produced glycoproteins in general have a different glycosylation pattern than their natural counterparts.
  • Such glycoproteins may also be prepared in transgenic animals, preferably in non-human animals, such as in transgenic rabbits, bovine, mice, rats, goats and sheep. The skilled person will understand that it will depend on the specific glycoprotein to be produced and on the amount which has to be produced, which transgenic animal is best used for production.
  • modifications to the structure of the carbohydrate chain of the protein such as different glycosylation, underglycosylation or overglycosylation may be introduced separately or in combination, simultaneously or consecutively, some types may be introduced to one part of the molecule, while others are introduced to another part of the molecule.
  • Preferred combinations of modifications contribute to the shortening of the half-life of the protein by exposing the galactose, N-acetylgalactosamine, mannose, fucose or phosphomannose moieties of the protein.
  • the C1INH with a shorter half-life has a half-life which is less than 60 or 50%, preferably less than 40, 30, 25 or 20% of the half-life of its naturally occurring counterpart
  • compositions based on C1INH with shorter half-life may be used both in situations where transient treatment is a pre-requisite, as well as in situations in which transient treatment is merely an advantage. This is for example the case when using a pharmaceutical composition which does not cause severe toxic side effects, but which side effects are still unpleasant for the individual who is treated.
  • C1INH with a shorter half-life which is used for transient treatment may be part of or combined with state of the art pharmaceutical compositions.
  • These pharmaceutical compositions typically comprise the C1INH with a shorter half-life in association with a carrier or excipient and, optionally, a pharmaceutically acceptable adjuvant.
  • compositions may be administered in a number of ways depending on whether local or systemic treatment is desired, the area to be treated and the stability of the active compound. Suitable formulations will depend on the method of administration.
  • the pharmaceutical composition is preferably administered by parenteral administration, such as for example by intravenous, intra-arterial, subcutaneous, intraperitoneal or intramuscular injection or infusion; or by intrathecal or intracranial administration. In a preferred embodiment it is administered by intravenous infusion.
  • parenteral administration such as for example by intravenous, intra-arterial, subcutaneous, intraperitoneal or intramuscular injection or infusion; or by intrathecal or intracranial administration. In a preferred embodiment it is administered by intravenous infusion.
  • Suitable formulations for parenteral administration are known in the art and are typically liquid formulations. These liquid formulations may for example be administered by an infusion pump.
  • the effective dose i.e. effective concentration and frequency
  • the effective dose will depend on the specific pharmaceutical composition which is used, the severity of the condition and the general state of the patient's health.
  • the effective dose of a pharmaceutical composition which is based on a C1INH with a shorter half-life may be found by routine optimisation.
  • a suitable starting point is the dose which is used for the equivalent pharmaceutical composition which is based on plasma-derived C1INH.
  • a great advantage of a pharmaceutical composition of the invention is that a high initial dosis may be used in treatment, which enhances the likelihood of successful treatment. This high initial dose is possible because the C1INH in the pharmaceutical composition of the invention shows a faster clearance than its natural counterpart.
  • a C1INH with shorter half-life may be used to treat any type of disease in which normally a plasma-derived C1INH is used.
  • underglycosylated C1 esterase INH may be used to replace human plasma derived C1INH.
  • C1INH may be used for the treatment of individuals suffering from any condition or disease associated with an absolute or relative deficiency of functional C1INH. Such deficiency may result in an insufficient control of C1INH on local or systemic activation of inflammatory systems involved in the pathophysiology of said conditions, including the complement and contact systems.
  • Such disorders include: Acquired angioedema (AAE) and hereditary angioedema (HAE), for which conditions acute treatment and short-term prophylaxis can be applied; Sepsis; septic shock, acute respiratory distress syndrome (ARDS), multiple organ failure (MOF) and preeclampsia, vascular leakage syndrome (VLS), graft versus host disease (GVHD), severe burns and thermal trauma; rheumatoid arthritis; systemic lupus erythematosus; meningitis: cardiopulmonary bypass (CPB), extra corporal circulation (ECC), and (hyper)acute graft rejection.
  • AAE Acquired angioedema
  • HAE hereditary angioedema
  • C1INH may also be used for the treatment of individuals suffering from any disorder associated with ischemic reperfusion injury, including: acute myocardial infarction (AMI); ischemic reperfusion injury after emergency coronary surgery for failed percutaneous transluminal coronary angioplasty (PCTA), or after any vascular surgery with blood vessel cross clamping (e.g. of aorta, leading to skeletal muscle ischemia); stroke; after hemorragic shock; after or during ECC; after/during CPB; after/during any transplantation surgery (lung, liver, kidney, heart); intestinal ischemia; pancreatitis after manipulation of pancreatic or bile duct (ERCP).
  • AMI acute myocardial infarction
  • PCTA percutaneous transluminal coronary angioplasty
  • vascular surgery with blood vessel cross clamping e.g. of aorta, leading to skeletal muscle ischemia
  • stroke after hemorragic shock; after or during ECC; after/during CPB; after/during any
  • recombinant human C1INH produced in rabbits is used instead of C1INH from human plasma.
  • the rabbit-derived human C1INH contains about 5-6 fold less sialic acid as compared to its natural counterpart and about 15% of its N-linked glycans are neutral carrying terminal mannose residues, whereas plasma derived C1INH has no oligomannose type glycosylation.
  • the rabbit recombinant human C1INH may be used in higher amounts than plasma derived C1INH without serious adverse side effects, while still having a beneficial effect.
  • underglycosylated human C1INH is administered intravenously at a dose of more than 25, 50 or 70 U/kg body weight of the individual, preferably more than 80, 100, 150 or 200 U/kg body weight of the individual.
  • One unit (U) of C1INH is the amount of C1INH present in 1 milliliter of human blood.
  • One such unit corresponds to approximately 275 microgram plasma derived C1INH. Assuming a molecular weight of 110,000 dalton, the concentration in human plasma of C1INH is 2.5 micromol per liter (Nuijens et al. (1989), J. Clin. Invest. 84:443).
  • the profiles of functional C1INH ( FIG. 1 ) indicated a full initial recovery and a dose-dependent clearance of rhC1INH, which indicates a saturable mechanism of elimination. This was confirmed by analysing the rate of clearance, half-lifes and endogenous infusion rate, which is shown in Table 2. These were dependent on the dose.
  • Baseline C4 levels and C4 responses were highly variable between subjects of the distinct dosage groups, which underlines the need to express individual C4 responses relative to individual C4 antigen values at baseline (normalised C4 antigen). Expression of C4 antigen normalised to baseline facilitates the comparison of C4 responses both within and between dosage groups.
  • the mean of individual baseline C4 levels is arbitrarily set at 100% and changes of C4 levels post-infusion are expressed as percentage change from baseline.
  • the increases in functional C1INH resulted in an initial dose-dependent decrease in mean normalised C4 (decrease of about 25% within one hour after 100 U/kg), which was followed by a dose-dependent increase in mean normalised C4 (about 200% after 100 U/kg) which response was highly variable within dosage groups.
  • C4 peak levels occurred at about 12 hours post-infusion and thereafter gradually declined to baseline.
  • An immediate dose-dependent effect of functional C1INH on plasma C4b/c was observed.
  • FIG. 3 shows that the magnitude of the decrease in C4b/c as well as its duration appeared dependent on the dose of functional C1INH.
  • Combining the profiles of functional C1INH and C4b/c revealed an inverse relationship between functional C1INH and C4b/c. The results indicated that cleavage of C4 starts to occur once functional C1INH drops below a level of about 70% of normal.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
US13/157,176 2003-05-16 2004-05-14 C1 inhibitor with short half-life transient treatment Expired - Lifetime USRE43691E1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US13/157,176 USRE43691E1 (en) 2003-05-16 2004-05-14 C1 inhibitor with short half-life transient treatment

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP03076466 2003-05-16
EM03076466 2003-05-16
PCT/NL2004/000330 WO2004100982A1 (en) 2003-05-16 2004-05-14 C1 inhibitor with short half-life for transient treatment
US13/157,176 USRE43691E1 (en) 2003-05-16 2004-05-14 C1 inhibitor with short half-life transient treatment
US10/557,026 US7544853B2 (en) 2003-05-16 2004-05-14 C1 inhibitor with short half-life transient treatment

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US10557026 Reissue 2007-02-21

Publications (1)

Publication Number Publication Date
USRE43691E1 true USRE43691E1 (en) 2012-09-25

Family

ID=33442800

Family Applications (2)

Application Number Title Priority Date Filing Date
US13/157,176 Expired - Lifetime USRE43691E1 (en) 2003-05-16 2004-05-14 C1 inhibitor with short half-life transient treatment
US10/557,026 Ceased US7544853B2 (en) 2003-05-16 2004-05-14 C1 inhibitor with short half-life transient treatment

Family Applications After (1)

Application Number Title Priority Date Filing Date
US10/557,026 Ceased US7544853B2 (en) 2003-05-16 2004-05-14 C1 inhibitor with short half-life transient treatment

Country Status (15)

Country Link
US (2) USRE43691E1 (pl)
EP (1) EP1626736B1 (pl)
JP (1) JP2007500741A (pl)
CN (1) CN100431604C (pl)
AU (1) AU2004238170B2 (pl)
CA (1) CA2525522A1 (pl)
CY (1) CY1123601T1 (pl)
DK (1) DK1626736T3 (pl)
ES (1) ES2830499T3 (pl)
HU (1) HUE052154T2 (pl)
NZ (1) NZ543646A (pl)
PL (1) PL1626736T3 (pl)
PT (1) PT1626736T (pl)
SI (1) SI1626736T1 (pl)
WO (1) WO2004100982A1 (pl)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9616111B2 (en) 2013-03-15 2017-04-11 Shire Viropharma Incorporated C1-INH compositions and methods for the prevention and treatment of disorders associated with C1 esterase inhibitor deficiency
US10441631B2 (en) * 2013-02-28 2019-10-15 Csl Behring Gmbh Therapeutic agent for amniotic fluid embolism

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060142220A1 (en) * 2002-10-17 2006-06-29 Berkel Patrick V Protein modification
JP2007500741A (ja) * 2003-05-16 2007-01-18 ファーミング・インテレクチュアル・プロパティー・ビー．ブイ． 一時的処置のための短い半減期を有するｃ１インヒビター
DK1830924T3 (da) 2004-12-23 2013-05-21 Csl Behring Gmbh Forebyggelse af thrombedannelse og/eller -stabilisering
PL2380587T3 (pl) * 2005-12-21 2018-03-30 Pharming Intellectual Property B.V. Zastosowanie inhibitora C1 do zapobiegania uszkodzeniu niedokrwiennoreperfuzyjnemu
CN105641688B (zh) * 2005-12-21 2020-06-09 法明知识产权股份有限公司 C1抑制剂在预防缺血-再灌注损伤中的应用
AU2007307375B2 (en) * 2006-10-10 2013-11-28 Regenesance B.V. Complement inhibition for improved nerve regeneration
PL2683397T3 (pl) * 2011-03-09 2018-01-31 Csl Behring Gmbh Inhibitory czynnika XII do podawania w zabiegach medycznych obejmujących kontakt z powierzchniami sztucznymi
EP2497489A1 (en) * 2011-03-09 2012-09-12 CSL Behring GmbH Factor XII inhibitors for the treatment of silent brain ischemia and ischemia of other organs
US20160058850A1 (en) * 2012-11-13 2016-03-03 Biogenius Llc Compositions and methods for treating inflammatory diseases of infectious and non-infectious origin
DK2964255T3 (da) 2013-03-08 2021-02-08 Csl Behring Gmbh Behandling og forebyggelse af fjerntliggende iskæmi-reperfusionsskade (IRI)
US10758550B2 (en) 2013-10-04 2020-09-01 Glenmark Specialty S.A. Treatment of allergic rhinitis using a combination of mometasone and olopatadine
WO2015054569A1 (en) * 2013-10-10 2015-04-16 Viropharma Holdings Limited Methods of inhibiting the alternative pathway of complement immune system activation and compositions used therein
JP2017506676A (ja) * 2014-02-28 2017-03-09 サンタラス インコーポレイテッド Ｃ１阻害剤を用いる遺伝性血管性浮腫の治療
WO2019166572A1 (en) 2018-02-28 2019-09-06 Pharming Intellectual Property B.V. Pharmaceutical system for transdermal administration of a c1 -esterase inhibitor
BR112020017626A2 (pt) * 2018-02-28 2020-12-22 Pharming Intellectual Property B.V. Tratamento e prevenção de pré-eclâmpsia
EP3895726A1 (en) * 2020-04-17 2021-10-20 Pharming Intellectual Property BV Using c1 esterase inhibitor to treat viral infection-related acute respiratory distress
CA3225079A1 (en) 2021-07-09 2023-01-12 Bruno Giannetti Using c1 esterase inhibitor to treat viral infection-related symptoms

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2601034A1 (fr) 1986-07-03 1988-01-08 Pasteur Institut Inhibiteur de l'activite de la c1-esterase plasmatique (c1-inhibiteur) et d'autres enzymes proteolytiques du groupe des proteases a serine, son procede de preparation, acides nucleiques codant pour cet inhibiteur, methodes de detection d'affections correlees aux defauts dudit inhibiteur a l'aide d'anticorps ou de sondes nucleotidiques et medicaments contenant ledit inhibiteur de synthese
WO1991006650A1 (en) 1989-10-27 1991-05-16 Cetus Corporation C1 inhibitor muteins and uses thereof
WO1992022320A1 (en) 1991-06-14 1992-12-23 Genentech, Inc. C1 inhibitor variants and treating inflammatory response with c1 inhibitor
EP0586909A2 (de) 1992-08-24 1994-03-16 BEHRINGWERKE Aktiengesellschaft Verwendung von C1-Inaktivator zur Herstellung eines Arzneimittels zur Prophylaxe und Therapie des Capillary Leak Syndroms und Kreislaufschocks
WO1996003051A1 (en) 1994-07-27 1996-02-08 Gene Pharming Europe B.V. Production of collagen in the milk of transgenic mammals
WO2001057079A2 (en) 2000-01-31 2001-08-09 Pharming Intellectual Property B.V. C1 inhibitor produced in the milk of transgenic mammals
US20050223416A1 (en) * 2000-01-31 2005-10-06 Pharming Intellectual Property B.V. C1 inhibitor produced in the milk of transgenic mammals
US7544853B2 (en) * 2003-05-16 2009-06-09 Pharming Intellectual Property B.V. C1 inhibitor with short half-life transient treatment
US8061532B2 (en) * 2000-05-24 2011-11-22 Millipore Corporation Process of forming multilayered structures

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2601034A1 (fr) 1986-07-03 1988-01-08 Pasteur Institut Inhibiteur de l'activite de la c1-esterase plasmatique (c1-inhibiteur) et d'autres enzymes proteolytiques du groupe des proteases a serine, son procede de preparation, acides nucleiques codant pour cet inhibiteur, methodes de detection d'affections correlees aux defauts dudit inhibiteur a l'aide d'anticorps ou de sondes nucleotidiques et medicaments contenant ledit inhibiteur de synthese
WO1991006650A1 (en) 1989-10-27 1991-05-16 Cetus Corporation C1 inhibitor muteins and uses thereof
WO1992022320A1 (en) 1991-06-14 1992-12-23 Genentech, Inc. C1 inhibitor variants and treating inflammatory response with c1 inhibitor
EP0586909A2 (de) 1992-08-24 1994-03-16 BEHRINGWERKE Aktiengesellschaft Verwendung von C1-Inaktivator zur Herstellung eines Arzneimittels zur Prophylaxe und Therapie des Capillary Leak Syndroms und Kreislaufschocks
WO1996003051A1 (en) 1994-07-27 1996-02-08 Gene Pharming Europe B.V. Production of collagen in the milk of transgenic mammals
WO2001057079A2 (en) 2000-01-31 2001-08-09 Pharming Intellectual Property B.V. C1 inhibitor produced in the milk of transgenic mammals
US20050223416A1 (en) * 2000-01-31 2005-10-06 Pharming Intellectual Property B.V. C1 inhibitor produced in the milk of transgenic mammals
US7067713B2 (en) * 2000-01-31 2006-06-27 Pharming Intellectual Property B.V. C1 Inhibitor produced in the milk of transgenic non-human mammals
US8061532B2 (en) * 2000-05-24 2011-11-22 Millipore Corporation Process of forming multilayered structures
US7544853B2 (en) * 2003-05-16 2009-06-09 Pharming Intellectual Property B.V. C1 inhibitor with short half-life transient treatment

Non-Patent Citations (22)

* Cited by examiner, † Cited by third party
Title
Akita, N., et al., "The effect of C 1 esterase inhibitor on ischemia: reperfusion injury in the rat brain," No To Shinkei, vol. 53(7), pp. 641-644 (2001) [Article in Japanese] English Abstract only.
Bork, et al., "Long-Term Prophylaxis with C1-inhibitor (C1 INH) Concentrate in Patients with Recurrent Angioedema Caused by Hereditary and Acquired C1-Inhibitor Deficiency," J. Allergy Clinical Immunology, vol. 83, pp. 677-682 (1989).
Bos et al. Expression of Recombinant C1-Inhibitor in the Methylotrophic. 2002, International Immunopharm., vol. 2, No. 9, pp. 1330, abs. 11. *
Bos, I.G.A., et al., "Recombinant human C1-inhibitor produced in Pichia pastoris has the same inhibitory capacity as plasma C1-inhibitor," Biochimica et Biophysica Acta, vol. 1648, pp. 75-83 (2003).
Carter P. et al., Euro J. Biochem. 173;163, (1988).
Chu, L. and D.K. Robinson, "Industrial choices for protein production by large-scale cell culture," Current Opinion in Biotechnology, vol. 12, pp. 180-187 (2001).
Cicardi, M. et al., Immunobiol. 199:366, (1998).
Davis A.E., Ann. Rev. Immunol. 6:595-628 (1988).
De Filippi, F et al., Transfusion 38:307, (1998).
Eldering, E. et al., "Expression of functional human C1 inhibitor in COS cells," J. Biol. Chem. 263(24), pp. 11776-11779 (1988).
Gonçalves, M.A.F.V, "A concise peer into the background, initial thoughts and practices in human gene therapy," Bioessays, vol. 27, pp. 506-517 (2005).
Hack, C. et al., LANCET, 339:8789 378, (1992).
Houdebine, L.M., "Transgenic Animal Bioreactor," Transgenic Res., vol. 9 (4-5), pp. 305-320 (2000).
Koles, K., et al., "Influence of Lactation Parameters on the N-Glycosylation of Recombinant Human C1 Inhibitor Isolated from the Milk of Transgenic Rabbits," Glycobiology, vol. 14(11), pp. 979-986 (2004).
Lamark, T., et al., "Expression of active C1 inhibitor in serpin domain of Escherichia coli," Protein Expression and Purification, vol. 22, pp. 349-358 (2001).
Marasini, B., et al., "Treatment of hereditary angioedema," Klin Wochenschr., vol. 56(16), pp. 819-823 (1978) [Article in German] English Abstract only.
Rai, M. and H. Padh, "Expression of systems for production of heterologous proteins," Current Science, vol. 80(9,10), pp. 1121-1128 (2001).
Schapira, M. et al., Complement 2:111 (1985).
Shoenberger, O.L., "Characterization of carbohydrate chains of C1-inhibitor and desialylated C1-inhibitor," FEBS, vol. 314, pp. 430-434 (1992).
Wolff, M.W., et al., "Expression of C1 esterase inhibitor by the baculovirus expression vector system: Preparation, purification and characterization," Protein Expression and Purification, vol. 22, pp. 414-421 (2001).
Wurm, F.M., "Production of recombinant protein therapeutics in cultivated mammalian cells," Nature Biotechnology, vol. 22(11), pp. 1393-1398 (2004).
Zurlo J. et al. Fertility and Sterility 54:64, (1990).

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10441631B2 (en) * 2013-02-28 2019-10-15 Csl Behring Gmbh Therapeutic agent for amniotic fluid embolism
US9616111B2 (en) 2013-03-15 2017-04-11 Shire Viropharma Incorporated C1-INH compositions and methods for the prevention and treatment of disorders associated with C1 esterase inhibitor deficiency
US10080788B2 (en) 2013-03-15 2018-09-25 Shire Viropharma Incorporated C1-INH compositions and methods for the prevention and treatment of disorders associated with C1 esterase inhibitor deficiency
US10105423B2 (en) 2013-03-15 2018-10-23 Shire Viropharma Incorporated C1-INH compositions and methods for the prevention and treatment of disorders associated with C1 esterase inhibitor deficiency
US10130690B2 (en) 2013-03-15 2018-11-20 Shire Viropharma Incorporated C1-INH compositions and methods for the prevention and treatment of disorders associated with C1 esterase inhibitor deficiency
US10201595B2 (en) 2013-03-15 2019-02-12 Shire Viropharma Incorporated C1-INH compositions and methods for the prevention and treatment of disorders associated with C1 esterase inhibitor deficiency
US11364288B2 (en) 2013-03-15 2022-06-21 Viropharma Biologics Llc C1-INH compositions and methods for the prevention and treatment of disorders associated with C1 esterase inhibitor deficiency
US11534482B2 (en) 2013-03-15 2022-12-27 Viropharma Biologics Llc C1-INH compositions and methods for the prevention and treatment of disorders associated with C1 esterase inhibitor deficiency

Also Published As

Publication number Publication date
WO2004100982A1 (en) 2004-11-25
US7544853B2 (en) 2009-06-09
CA2525522A1 (en) 2004-11-25
US20070185011A1 (en) 2007-08-09
ES2830499T3 (es) 2021-06-03
EP1626736A1 (en) 2006-02-22
AU2004238170A1 (en) 2004-11-25
HUE052154T2 (hu) 2021-04-28
DK1626736T3 (da) 2020-09-28
CY1123601T1 (el) 2022-03-24
CN100431604C (zh) 2008-11-12
CN1791425A (zh) 2006-06-21
PT1626736T (pt) 2020-10-13
AU2004238170B2 (en) 2009-11-05
JP2007500741A (ja) 2007-01-18
PL1626736T3 (pl) 2021-05-04
NZ543646A (en) 2009-09-25
SI1626736T1 (sl) 2021-04-30
EP1626736B1 (en) 2020-09-16

Similar Documents

Publication Publication Date Title
USRE43691E1 (en) C1 inhibitor with short half-life transient treatment
Manusama et al. Synergistic antitumour effect of recombinant human tumour necrosis factor a with melphalan in isolated limb perfusion in the rat
US6531121B2 (en) Protection and enhancement of erythropoietin-responsive cells, tissues and organs
DE69527966T2 (de) Pharmazeutische zubereitung für die subkutane, intramuskuläre oder intradermale verabreichung von faktor viii
DE60112429T2 (de) Verwendung von faktor vii-a und faktor xiii enthaltenden pharmazeutischen verbindungen
JP4750947B2 (ja) 脳虚血の処置法及び脳虚血の処置のためのエリスロポエチン又はエリスロポエチン誘導体類の使用
US9561263B2 (en) Treatment of inflammatory illnesses with ACE2
RU2225221C2 (ru) ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ Эритропоэтина
Brady et al. Enzyme replacement therapy in Fabry disease
NO20032912L (no) Beskyttelse, gjenoppbygging og styrking av erytropoietinresponsive celler, vev og organer.
EP0082731A1 (en) The use of peptides as medicaments
US20040209812A1 (en) Use of erythropoietin in stroke recovery
US20040198652A1 (en) Methods and compositions for preventing and treating septic shock and endotoxemia
Jacob Pulse steroids in hematologic diseases
JP2009510008A (ja) 神経変性障害の処置
US20180117126A1 (en) Treatment of inflammatory illnesses with ace2
EP0914829B1 (en) Preventives and/or remedies for multiple organ failure
JP7016124B2 (ja) 虚血性疾患の治療剤
US8895505B2 (en) Method of treatment of type 2 diabetes
JPH09506115A (ja) 細胞毒性薬の副作用を軽減するためのトランスフェリン組成物
EP1947115B1 (en) Combination of glycoisoforms for the treatment or prevention of septicemia, transgenic cell line that produces erythropoietin glycoisoforms, pharmaceutical composition comprising said combination, method of obtaining the cell line, method of producing the combination of glycoisoforms and methods for the treatment and prevention of septicaemia
JP4029221B2 (ja) 心筋梗塞予防治療剤
JPH0867636A (ja) 播種性血管内凝固症候群（ｄｉｃ）の予防治療薬
JP3806945B2 (ja) ヒト由来アンチトロンビン−ｉｉｉの新規用途
EP0739633A2 (en) Use of antithrombin III to increase placental blood flow

Legal Events

Date Code Title Description
FPAY Fee payment

Year of fee payment: 4

PTEF Application for a patent term extension

Free format text: PRODUCT NAME: RUCONEST (RECOMBINANT C1ESTERASE INHIBITOR (RHC1INH); REQUESTED FOR 557 DAYS

Filing date: 20140912

Expiry date: 20240514

FEPP Fee payment procedure

Free format text: PAT HOLDER NO LONGER CLAIMS SMALL ENTITY STATUS, ENTITY STATUS SET TO UNDISCOUNTED (ORIGINAL EVENT CODE: STOL); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

FPAY Fee payment

Year of fee payment: 8

AS Assignment

Owner name: SILICON VALLEY BANK, GREAT BRITAIN

Free format text: SECURITY INTEREST;ASSIGNOR:PHARMING INTELLECTUAL PROPERTY B.V.;REEL/FRAME:040839/0865

Effective date: 20161207

AS Assignment

Owner name: ORBIMED ROYALTY OPPORTUNITIES II, LP, NEW YORK

Free format text: AMENDED AND RESTATED INTELLECTUAL PROPERTY SECURITY AGREEMENT;ASSIGNOR:PHARMING INTELLECTUAL PROPERTY B.V.;REEL/FRAME:042481/0139

Effective date: 20170515

PTER Rejection of a request for patent term extension (for eg. ineligible, dismissal, withdrawal, etc)

Free format text: PRODUCT NAME: RUCONEST (RECOMBINANT C1ESTERASE INHIBITOR (RHC1INH)

Filing date: 20140912

Expiry date: 20240514

AS Assignment

Owner name: PHARMING TECHNOLOGIES B.V., NETHERLANDS

Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:ORBIMED ROYALTY OPPORTUNITIES II, LP;REEL/FRAME:051722/0304

Effective date: 20200123

Owner name: PHARMING INTELLECTUAL PROPERTY B.V., NETHERLANDS

Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:ORBIMED ROYALTY OPPORTUNITIES II, LP;REEL/FRAME:051722/0304

Effective date: 20200123

Owner name: PHARMING HEALTHCARE, INC., NETHERLANDS

Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:ORBIMED ROYALTY OPPORTUNITIES II, LP;REEL/FRAME:051722/0304

Effective date: 20200123

Owner name: PHARMING AMERICAS B.V., NETHERLANDS

Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:ORBIMED ROYALTY OPPORTUNITIES II, LP;REEL/FRAME:051722/0304

Effective date: 20200123

Owner name: PHARMING B.V., NETHERLANDS

Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:ORBIMED ROYALTY OPPORTUNITIES II, LP;REEL/FRAME:051722/0304

Effective date: 20200123

Owner name: BROEKMAN INSTITUUT B.V., NETHERLANDS

Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:ORBIMED ROYALTY OPPORTUNITIES II, LP;REEL/FRAME:051722/0304

Effective date: 20200123

Owner name: PHARMING GROUP N.V., NETHERLANDS

Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:ORBIMED ROYALTY OPPORTUNITIES II, LP;REEL/FRAME:051722/0304

Effective date: 20200123

MAFP Maintenance fee payment

Free format text: PAYMENT OF MAINTENANCE FEE, 12TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1553); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

Year of fee payment: 12